“We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals,” said Kevin Hykes, President and Chief Executive ...

CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: ...

When medication stops working for people with congestive heart failure there are few options. A few months ago, Joe Knox couldn't take a simple walk due to his congestive heart failure. "I couldn't ...

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

CVRx's stock price has risen 38% following the BeAT-HF trial readouts, with potential catalysts for further growth, including Barostim and sentiment factors. The company is in interactive discussions ...

PITTSBURGH (KDKA) -- After a heart attack, Fred Fortson's heart didn't work as well as it should. "Walking upstairs, walking a distance, and I started to get shortening of breath," Fortson said. As ...

MINNEAPOLIS, CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ...

MEMPHIS, Tenn. - Last winter, retired hospice chaplain Richard Corum had come to terms with dying. The 66-year-old from Lakeland was suffering from advanced heart failure. He had his funeral planned ...

CVRx shares were 19% higher, at $8.48, after the company said that the Centers for Medicare and Medicaid Services has proposed keeping CVRx's Barostim implant procedure as part of the New Technology ...

CVRx recently reported preliminary revenue for the first quarter of 2025, which fell short of expectations. The company's revenue for Q1 2025 was approximately $12.3 million, representing a 15% ...